FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 02/22/2007 |
3. Issuer Name and Ticker or Trading Symbol
LA JOLLA PHARMACEUTICAL CO [ LJPC ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 2,718 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Options (right to buy) | (1) | 10/01/2011 | Common Stock | 700 | $20.3 | D | |
Stock Options (right to buy) | (2) | 12/14/2011 | Common Stock | 480 | $35.5 | D | |
Stock Options (right to buy) | (2) | 07/18/2012 | Common Stock | 460 | $25.45 | D | |
Stock Options (right to buy) | (2) | 11/21/2012 | Common Stock | 660 | $29.5 | D | |
Stock Options (right to buy) | (2) | 05/12/2013 | Common Stock | 750 | $14.85 | D | |
Stock Options (right to buy) | (2) | 09/18/2013 | Common Stock | 750 | $23.55 | D | |
Stock Options (right to buy) | (3) | 05/21/2014 | Common Stock | 1,599 | $14.8 | D | |
Stock Options (right to buy) | (4) | 07/29/2014 | Common Stock | 100 | $10.6 | D | |
Stock Options (right to buy) | (5) | 04/25/2015 | Common Stock | 2,646 | $2.4 | D | |
Stock Options (right to buy) | (5) | 05/19/2015 | Common Stock | 1,354 | $2.15 | D | |
Stock Options (right to buy) | (5) | 10/10/2015 | Common Stock | 5,414 | $4.2 | D | |
Stock Options (right to buy) | (5) | 04/17/2016 | Common Stock | 20,301 | $4.46 | D | |
Stock Options (right to buy) | (6) | 02/05/2017 | Common Stock | 25,000 | $3.08 | D |
Explanation of Responses: |
1. The stock options vested and became exercisable with respect to 33% of the underlying shares on 10/1/2002 and with respect to an additional 67% of the underlying shares monthly during the following 2 years. |
2. 1/36 of the stock options vested and became exercisable each month following the grant date. |
3. 1/2 of the stock options vest on the date that the Company receives approval to market its lead drug candidate for the treatment of lupus and 1/24 of the remaining stock options vest at the end of each month thereafter until all of the stock options are vested. Notwithstanding the foregoing, if marketing approval is not obtained between the grant date and the three year anniversary of the grant date, then 100% of the stock options will vest on the three year anniversary of the grant date. |
4. The stock options vested and became exercisable on the grant date. |
5. 1/36 of the stock options vest and become exercisable each month following the grant date. |
6. 1/48 of the stock options vest and become exercisable each month following the grant date. |
Remarks: |
/s/ Gail A. Sloan Attorney-in-fact for Luke Seikkula | 03/01/2007 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |